For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint - - PDF document

for personal use only
SMART_READER_LITE
LIVE PREVIEW

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint - - PDF document

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Companys Annual General Meeting today. For further


slide-1
SLIDE 1

The Hydroponics Company Limited (ASX: THC) ACN: 614 508 039 Suite 305, Level 3, 35 Lime Street Sydney NSW 2000

ASX RELEASE (23rd March 2018)

AGM PowerPoint Presentaion

In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company’s Annual General Meeting today. For further information, please contact: Jarrod White Company Secretary The Hydroponics Company Limited Suite 305, Level 3, 35 Lime Street Sydney NSW 2000 P: +61 2 8296 0000 E: jarrod.white@thcl.com.au Michael Lovesey Director Corporate Media Relations MMR Corporate Services Pty Ltd Level 2, 131 Macquarie Street Sydney, NSW 2000 Australia P: +61 2 9251 7177 M: +61 449 607 636 E: michaell@mmrcorporate.com About The Hydroponics Company www.thcl.com.au THC is at the forefront of developing a leading, diversified worldwide cannabis business, focusing on two core business units: Development and delivery of medicinal cannabis, and manufacturing and distribution of hydroponics equipment, materials and nutrients.

For personal use only

slide-2
SLIDE 2

B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Annual General Meeting

March 2018

ASX:THC

For personal use only

slide-3
SLIDE 3

DISCLAIMER

2 The material in this presentation (material) is not and does not constitute an offer, invitation or recommendation to subscribe for, or purchase any security in The Hydroponics Company Limited (THC) nor does it form the basis of any contract or commitment. In the event that an offer, invitation or recommendation to subscribe for, or purchase any security in THC is made in the future, a Prospectus will be made available in relation to the same. If and when the Prospectus becomes available it may be downloaded from the THC’s website at www.thcl.com.au. At that time any person wishing to make an investment in THC must consider the Prospectus in deciding whether to acquire the security and must complete the application form that will be in or will accompany the Prospectus. THC makes no representation or warranty, express or implied, as to the accuracy, reliability or completeness of this material. THC, its directors, employees, agents and consultants shall have no liability, including liability to any person by reason of negligence or negligent misstatement, for any statements,

  • pinions, information or matters, express or implied, arising
  • ut of, contained in or derived from, or for any omissions

from this material except liability under statute that cannot be excluded. Statements contained in this material, particularly those regarding possible or assumed future performance, costs, dividends, production levels or rates, prices, resources, reserves or potential growth of THC, industry growth or other trend projections are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual events and results may differ materially from those expressed or forecasted in forward-looking statements due to a number of

  • factors. The principal important risk factors that could cause THC’s

actual performance and future events and actions to differ materially from such forward-looking statements, include, but are not limited to, continuing volatility in the capital or credit markets and other changes in the securities and capital markets, changes in market prices of THC’s investments, the occurrence of one or more catastrophic events, such as an earthquake, hurricane, or act

  • f terrorism, changes in laws or regulations, changes in income

tax laws, and changes in general economic and market factors that affect the prices of securities or the industries in which it does business. This presentation includes certain statements, estimates and projections that rely upon various assumptions. Those assumptions may or may not prove to be correct. The Presentation does not purport to contain all the information that a prospective investor may require. The information may not be appropriate for all persons, and it is not possible for The Hydroponics Company Limited to have any regard to the investment objectives, financial situation and particular needs of each recipient who reads or uses this information.

For personal use only

slide-4
SLIDE 4

DUAL STRATEGY

Focused on a two-pronged strategy 1) to expand profitable Canadian operations & 2) develop local medicinal cannabis market

3

AUSTRALIA Development and delivery of medicinal cannabis Accelerating market uptake- local & imported products 2 of 3 licences granted, R&D and Medicinal Cannabis licence Manufacturing licence lodged Q4-17 CANADA Manufacturing and distribution of hydroponics equipment, materials and nutrients Driving profitable growth through

  • Expansion of existing product catalogue
  • Acquisition plan under development

For personal use only

slide-5
SLIDE 5

CORPORATE STRUCTURE

Share Price – THC Shares on Issue Free trading shares Market Cap Cash Approx

Top 20 Number of shareholders

$0.60 123.7

million

85.9

million

$74

million

$12.8

million

45% 5,400

(IPO: 750)

The Hydroponics Company Limited ASX: THC

4

Data as of 21st March THC share price

For personal use only

slide-6
SLIDE 6

SURGING GLOBAL CANNABIS GROWTH

5

North American Cannabis market estimated

US$20B by 2021

United States 30 US States medicinal cannabis legalised 8 US States recreational marijuana legalised Canada Medicinal cannabis legalised Recreational cannabis to be legalised in 2018 Current and real growth opportunities Australia Developing market 1.8m patients with neuropathic pain

For personal use only

slide-7
SLIDE 7

CANNDEO

This division aims to lead the development of an accelerated path to market encompassing local and imported products, IT solutions and a variety of clinical solutions to drive growth in the prescriber base Accelerated Access to Medicinal Cannabis Product Development Accelerated path to market Australian Manufacturing Sales of Proprietary Products Future IP Research

6

For personal use only

slide-8
SLIDE 8

A NEW CLASS OF MEDICINAL PRODUCTS

Accelerating path to market

Clear import strategy for bringing medicinal cannabis to the Australian market. +17 years of Cannabis sativa breeding, variety selection and growth management Clinical studies due to commence

Target multiple markets

with high quality cannabidiol (CBD) Two of three required licences under Government licensing

program

7

For personal use only

slide-9
SLIDE 9

INTERNATIONAL SUPPLY AGREEMENTS

8

Distribution Agreement with Endoca - EUROPE A recognised leader in the supply of high quality CBD products worldwide European pioneers in extraction and purification, sales exceeding 50 million Euro per annum Focus on distributing world’s best medicinal cannabis products in Australia CBD oil, CBD capsules and a unique CBD+CBDA oil Strategic Alliance with BOL Pharma - ISRAEL One of Israel’s leading suppliers of medicinal cannabis solutions Pioneering creation of medicinal cannabis industry in Israel since 2007 Partnership to develop Australian market through Canndeo Supplying products for Clinical Trials AUSTRALIA

8

For personal use only

slide-10
SLIDE 10

AUSTRALIAN MARKET STATISTICS

9

Clinical Condition Market Size Endoca B.V. BOL Pharma Autism +230,000

(Source: Social Care Australia)

Dementia +400,000

(Source: Dementia Australia)

Epilepsy +250,000

(Source: Epilepsy Foundation)

Parkinson’s ~70,000

(Source: Parkinson’s Australia)

Tourette’s Syndrome

~45,000 (Source: ABC News Article)

For personal use only

slide-11
SLIDE 11

NATIONAL ACCESS CANNABIS

10

  • NAC-A leading

Canadian clinic group

  • Licence to use all IP in

Australia including prescribing guidelines

  • Assessing local

regulatory framework

For personal use only

slide-12
SLIDE 12

CANNDEO ACHIEVEMENTS SINCE IPO

11

  • Medicinal Cannabis Research Licence Granted July 2017
  • Clinical Trial partner
  • Medicinal Cannabis Prescription and Dispensing Portal
  • Medicinal Cannabis Licence granted October 2017
  • Manufacturing Licence application lodged
  • Licence Agreement with National Access Cannabis
  • Completion of Australian growing facilities

For personal use only

slide-13
SLIDE 13

CANNDEO INDICATIVE TIMELINE*

Further investment in market development Local market expansion

12

2018 Q3/4 2018 Q1/2 2019 Q1/2

*Performance and dates are subject to change and are indicative only.

  • BOL Pharma Clinical trial

commencement Market expansion through international partner sales & licensing Permit from ODC for cultivation Local Market development through clinic expansion Clinical Trial development

For personal use only

slide-14
SLIDE 14

Revenue growth from existing customer base Exclusive agreements for new agencies

ACQUISITIONS CRYSTAL MOUNTAIN/DRAGON VISION (CMDV)

Optimisation of business model Due Diligence on quality Canadian asset progressing Highly fragmented market with an

  • pportunity to develop significant

national local supplier

CANADIAN MARKET OPPORTUNITIES

13

Expansion of the Canadian market leading to multiple opportunities for revenue growth

For personal use only

slide-15
SLIDE 15

CRYSTAL MOUNTAIN PRODUCTS

Expansion plans underway for Canadian operations

14

New distribution plans to expand across Canada Trading profitably for 5+ years Expanded product portfolio Over 600 products,

9 trademarks

Strong distribution

networks

For personal use only

slide-16
SLIDE 16

CRYSTAL MOUNTAIN

Proprietary trademarked products include:

  • Lighting and power supplies
  • Lighting relays and Climate control
  • Ventilation and Trimming
  • Extraction bags
  • Plant rotation systems
  • Eyewear
  • Nutrients and accessories

100% owned by THC Wholesale network in Canada Strong sourcing and quality control team in China Fast paced and innovative R&D Division with increased resources offering considerable growth potential

15

DRAGON VISION MANUFACTURING

For personal use only

slide-17
SLIDE 17

SUMMARY

Investment Highlights

16

  • Only ASX listed entity with established revenue streams
  • Due Diligence on Canadian asset-strong EBITDA and

growth opportunities

  • 2 out of 3 Medicinal Cannabis Licenses granted
  • Manufacturing license lodged – in Q4-17
  • Canndeo focus on rapid expansion of local market

through clinic and clinical trial expansion

For personal use only

slide-18
SLIDE 18

THANK YOU

The Hydroponics Company Limited

www.thcl.com.au www.crystalmountainproducts.com www.canndeo.com Michael Lovesey – MMR Corporate Level 2, 131 Macquarie St, Sydney 2000 +61-9251-7177 +61-449-607-636

For personal use only